Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Effect of a serotonin reuptake inhibitor on irritability, apathy, and psychotic symptoms in patients with Alzheimer's disease.

Siddique H, Hynan LS, Weiner MF.

J Clin Psychiatry. 2009 Jun;70(6):915-8. doi: 10.4088/JCP.08m04828.

2.

[In Alzheimer's disease, the clinical expression of behavioral and psychological signs and symptoms is early and specific of neuropathological stages].

Michel BF, Luciani V, Geda YE, Sambuchi N, Paban V, Azorin JM.

Encephale. 2010 Sep;36(4):314-25. doi: 10.1016/j.encep.2009.10.012. French.

PMID:
20850603
3.

The effects of olanzapine in reducing the emergence of psychosis among nursing home patients with Alzheimer's disease.

Clark WS, Street JS, Feldman PD, Breier A.

J Clin Psychiatry. 2001 Jan;62(1):34-40.

PMID:
11235926
4.

Two cases of olfactory reference syndrome responding to an atypical antipsychotic and SSRI.

Michael S, Boulton M, Andrews G.

Aust N Z J Psychiatry. 2014 Sep;48(9):878-9. doi: 10.1177/0004867414526791. No abstract available.

PMID:
24604919
5.

Donepezil as add-on treatment of psychotic symptoms in patients with dementia of the Alzheimer's type.

Bergman J, Brettholz I, Shneidman M, Lerner V.

Clin Neuropharmacol. 2003 Mar-Apr;26(2):88-92.

PMID:
12671528
6.

Delusions and hallucinations in Alzheimer's disease: prevalence and clinical correlates.

Bassiony MM, Steinberg MS, Warren A, Rosenblatt A, Baker AS, Lyketsos CG.

Int J Geriatr Psychiatry. 2000 Feb;15(2):99-107.

PMID:
10679840
7.

Incidence of and risk factors for hallucinations and delusions in patients with probable AD.

Paulsen JS, Salmon DP, Thal LJ, Romero R, Weisstein-Jenkins C, Galasko D, Hofstetter CR, Thomas R, Grant I, Jeste DV.

Neurology. 2000 May 23;54(10):1965-71.

PMID:
10822438
8.

Risk factors for behavioral abnormalities in mild cognitive impairment and mild Alzheimer's disease.

Apostolova LG, Di LJ, Duffy EL, Brook J, Elashoff D, Tseng CH, Fairbanks L, Cummings JL.

Dement Geriatr Cogn Disord. 2014;37(5-6):315-26. doi: 10.1159/000351009.

9.

A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia.

Pollock BG, Mulsant BH, Rosen J, Mazumdar S, Blakesley RE, Houck PR, Huber KA.

Am J Geriatr Psychiatry. 2007 Nov;15(11):942-52.

PMID:
17846102
10.

Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients.

Pollock BG, Mulsant BH, Rosen J, Sweet RA, Mazumdar S, Bharucha A, Marin R, Jacob NJ, Huber KA, Kastango KB, Chew ML.

Am J Psychiatry. 2002 Mar;159(3):460-5.

PMID:
11870012
11.

Classification of Neuropsychiatric Symptoms Requiring Antipsychotic Treatment in Patients with Alzheimer's Disease: Analysis of the CATIE-AD Study.

Nagata T, Shinagawa S, Nakajima S, Plitman E, Mihashi Y, Hayashi S, Mimura M, Nakayama K.

J Alzheimers Dis. 2016;50(3):839-45. doi: 10.3233/JAD-150869.

PMID:
26836181
12.

Psychotic symptoms and physically aggressive behavior in Alzheimer's disease.

Gilley DW, Wilson RS, Beckett LA, Evans DA.

J Am Geriatr Soc. 1997 Sep;45(9):1074-9.

PMID:
9288014
13.

Delusions in Patients with Alzheimer's Disease: A Multidimensional Approach.

D'Onofrio G, Panza F, Sancarlo D, Paris FF, Cascavilla L, Mangiacotti A, Lauriola M, Paroni GH, Seripa D, Greco A.

J Alzheimers Dis. 2016;51(2):427-37. doi: 10.3233/JAD-150944.

PMID:
26890768
14.
15.

Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial.

Porsteinsson AP, Drye LT, Pollock BG, Devanand DP, Frangakis C, Ismail Z, Marano C, Meinert CL, Mintzer JE, Munro CA, Pelton G, Rabins PV, Rosenberg PB, Schneider LS, Shade DM, Weintraub D, Yesavage J, Lyketsos CG; CitAD Research Group..

JAMA. 2014 Feb 19;311(7):682-91. doi: 10.1001/jama.2014.93.

16.

Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease.

De Deyn PP, Carrasco MM, Deberdt W, Jeandel C, Hay DP, Feldman PD, Young CA, Lehman DL, Breier A.

Int J Geriatr Psychiatry. 2004 Feb;19(2):115-26.

PMID:
14758577
17.

The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer's disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trials.

Katz I, de Deyn PP, Mintzer J, Greenspan A, Zhu Y, Brodaty H.

Int J Geriatr Psychiatry. 2007 May;22(5):475-84.

PMID:
17471598
18.

The Neuropsychiatric Inventory-Clinician rating scale (NPI-C): reliability and validity of a revised assessment of neuropsychiatric symptoms in dementia.

de Medeiros K, Robert P, Gauthier S, Stella F, Politis A, Leoutsakos J, Taragano F, Kremer J, Brugnolo A, Porsteinsson AP, Geda YE, Brodaty H, Gazdag G, Cummings J, Lyketsos C.

Int Psychogeriatr. 2010 Sep;22(6):984-94. doi: 10.1017/S1041610210000876.

19.

Behavioral and psychological symptoms in Alzheimer's disease: frequency and relationship with duration and severity of the disease.

Piccininni M, Di Carlo A, Baldereschi M, Zaccara G, Inzitari D.

Dement Geriatr Cogn Disord. 2005;19(5-6):276-81.

PMID:
15775717
20.

Effect of second-generation antipsychotics on caregiver burden in Alzheimer's disease.

Mohamed S, Rosenheck R, Lyketsos CG, Kaczynski R, Sultzer DL, Schneider LS.

J Clin Psychiatry. 2012 Jan;73(1):121-8. doi: 10.4088/JCP.10m06574.

Supplemental Content

Support Center